Ewing sarcoma: Current concepts in diagnosis and treatment

Current Opinion in Pediatrics

Volumn 15, Issue 1, 2003, Pages 53-57

  Kennedy, John G ^a   Frelinghuysen, Peter ^a   Hoang, Bang H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; IRINOTECAN; KI 67 ANTIGEN; NEU DIFFERENTIATION FACTOR; PROTEIN P53; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VINCRISTINE;

ASPIRATION BIOPSY; BONE RADIOGRAPHY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 11; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIAPHYSIS; EWING SARCOMA; FATIGUE; FEVER; GAIT DISORDER; HUMAN; IMMUNOHISTOCHEMISTRY; LIMB SALVAGE; OSTEOSARCOMA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; BONE NEOPLASMS; CHILD; HUMANS; PROGNOSIS; SARCOMA, EWING'S; SURVIVAL RATE; TIME FACTORS;

EID: 0037304435     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200302000-00009     Document Type: Review

References (27)

1. Gou W, Xu W, Huvos AG, et al.: Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl) 1999, 112:1101-1104.
2. De Avala E, Panizo A, Antonescu CR, et al.: Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000, 156: 849-855.
3. Amir G, Issakov J, Meller I, et al.: Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome. Hum Pathol 2002, 33:170-174.
4. Wei G, Antonescu CR, de Alava E, et al.: Prognostic impact of INK4 deletion in Ewing sarcoma. Cancer 2000, 89:793-799.
5. Thomas DG, Giordano TJ, Sanders D, et al.: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002, 8:788-793.
6. Scully Sp, Temple HT, O'keefe RJ, et al: Role of surgical resection in pelvic Ewing's sarcoma. J Clin Oncol 1995, 13(9):2336-2341.
7. Kennedy JG, Eustace S, Caufield R, et al.: Extraskeletal Ewing's sarcoma: a case report and review of the literature. Spine 2000, 25:1996-1999.
8. Wunder JS, Paulian G, Huvos AG, et al.: The histologic response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998, 80:1020-1033.
9. Frostad B, Tani E, Brosjo O, et al.: Fine needle aspiration cytology in the diagnosis and management of children and adolescents with Ewing sarcoma and peripheral primitive neuroectodermal tumor. Med Pediatr Oncol 2002, 38:33-40.
10. Mankin HJ, Mankin CJ, Simon MA: The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996, 78:656-663.
11. Farley FA, Healey JH, Caparros-Sison B, et al.: Lactate dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcoma. Cancer 1987, 59:1245-1248.
12. Wagner LM, Neel MD, Pappo AS, et al.: Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol 2001, 23:568-571.
13. Lam CH, Nagib MG: Nonteratomatous tumors in the pediatric sacral region. Spine 2002, 27:284-287.
14. Yang DC, Ratani RS, Mittal PK, et al.: Radionuclide three-phase whole-body bone imaging. Clin Nucl Med 2002, 27:419-426.
15. Caluser CI, Abdel-Dayem HM, Macapinlac HA, et al.: The value of Thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 1994, 21:1198-1205.
16. Wexler LH, Delaney TF, Tsokos M, et al.: Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996, 78:901-911.
17. Kushner BH, Meyers PA, Gerald WL, et al.: Very high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995, 13:2796-2804.
18. Rodriguez-Galindo C, Billups CA, Kun LE, et al.: Survival after recurrence of Ewing tumors: the St. Jude Children's Research Hospital experience, 1979-1999. Cancer 2002, 94:561-569. •• A retrospective analysis of 71 patients with local, distant, and both local and distant recurrences was undertaken to determine outcomes as well as factors affecting prognosis. Although recurrent disease in Ewing sarcoma carried a very poor prognosis, this study identified several factors to stratify patients for more intensive therapy.
19. Cosetti M, Wexler LH, Calleja E, et al.: Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002, 24:101-105. • Irinotecan promising single-agent activity against solid tumors, particularly rhabdomyosarcoma and its tolerability, warranted further investigation of this agent.
20. Toretsky JA, Steinberg SM, Thakar M, et al.: Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001, 92:2941-2947. • IGF-1 level was significantly lower in patients with bone or bone marrow metastasis when compared with patients without metastasis. There was a trend toward better survival in patients with a high IGFBP-3 to IGF-1 ratio.
21. Merchant TE, Kushner BH, Sheldon JM, et al.: Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma. Med Pediatr Oncol 1999, 33:65-70.
22. Schuck A, Rube C, Konemann S, et al.: Postoperative radiotherapy in the treatment of Ewing tumors: influence of the interval between surgery and radiotherapy. Strahlenther Onkol 2002, 178:25-31.
23. Sluga M, Windhager R, Lang S, et al.: The role of surgery and resection margins in the treatment of Ewing sarcoma. Clin Orthop 2001, 392:394-399.
24. Krishnan A, Bhatia S, Slovak ML, et al.: Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000, 95:1588-1593.
25. Park S, Brice P, Noguerra ME, et al.: Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2000, 26:321-326.
26. Kawai A, Healey JH, Boland PJ, et al.: A rotating-hinge knee replacement for malignant tumors of the femur and tibia. J Arthoplasty 1999, 14:187-196.
27. De Alava E, Kawai A, Healey JH, et al.: EWS-FLI1 transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998, 16:1248-1255.